AMENDMENTS TO THE CLAIMS

1. (Currently Amended) An isolated antigenic composition, which composition comprises ~~comprising at least one antigen, wherein said at least one antigen comprises at least part of a protein of *Streptococcus equi subsp equi*, and said at least part of said protein comprises at least one antigenic epitope or antigenic determinant of *Streptococcus equi*, and wherein said protein is comprised of EAG comprising an amino acid sequence according to SEQ ID NO: 1, or an analog thereof~~

(i) a first antigen, which first antigen comprises at least part of an isolated protein of *Streptococcus equi* subsp *equi*, which protein is designated EAG and which at least part of said protein comprises at least one antigenic epitope or antigenic determinant of *Streptococcus equi*, and

which first antigen comprises at least the N-terminal amino acid sequence of EAG, which comprises the amino acid sequence of SEQ ID NO:1,

(ii) a second antigen, which second antigen comprises at least part of an isolated protein of *Streptococcus equi*, which protein is designated SEC and comprises the amino acid sequence of SEQ ID NO:4, and which at least part of said protein comprises at least one antigenic epitope or antigenic determinant of *Streptococcus equi*, and

which second antigen comprises at least the N-terminal collagen-binding part of SEC which comprises the amino acid sequence of SEQ ID NO:22, and

(iii) a third antigen, which third antigen comprises at least part of an isolated protein of *Streptococcus equi*, which protein is designated SclC and comprises the amino acid sequence of SEQ ID NO:23 and which at least part of said protein comprises at least one antigenic epitope or antigenic determinant of *Streptococcus equi*, and

which third antigen comprises at least the immunogenic fragment of SclC, which fragment comprises the amino acid sequence of SEQ ID NO:27.

2. (Currently Amended) The isolated antigenic composition of claim 1, ~~which comprises at least one further antigen that comprises at least part of a fibronectin-binding protein of *Streptococcus equi*, said at least part of said protein comprising at least one antigenic epitope or antigenic determinant of *Streptococcus equi*, and wherein said protein is selected from the group consisting of FNZ comprising an amino acid sequence according to SEQ ID NO: 2 and SFS comprising an amino acid sequence according to SEQ ID NO: 3, or an analog thereof~~

wherein said antigens are comprised of the N-terminal part of EAG in accordance with claim 1 (i), the collagen-binding part of SEC in accordance with claim 1 (ii), which collagen binding part comprises the amino acid sequence of SEQ ID NO:22 and the immunogenic fragment of SclC in accordance with claim 1 (iii), which fragment is designated SCL C1 and provokes production of antibodies, and which fragment comprises the amino acid sequence of SEQ ID NO:27.

3. (Currently Amended) The isolated antigenic composition of claim 1, ~~which comprises at least one further antigen that comprises at least part of a protein of *Streptococcus equi* and said at least part of said protein comprises an antigenic epitope or an antigenic determinant of *Streptococcus equi*, and wherein said protein is comprised of SEC comprising an amino acid sequence according to SEQ ID NO: 4, or an analog thereof~~

wherein said collagen binding part of SEC comprises the amino acid sequence of SEQ ID NO:20 and is designated SEC2.16.

4. (Currently Amended) The isolated antigenic composition of claim 1, ~~which comprises an N-terminal fragment of a protein selected from the group consisting of EAG and FNZ~~ wherein said third antigen is comprised of SCL C1 comprising the amino acid sequence of SEQ ID NO: 27.

5. (Withdrawn, Currently Amended) The isolated antigenic composition of claim [[3]] 1, ~~wherein said antigens are comprised of at least part of EAG, FNZ, SFS, and SEC, optionally, said at least part of EAG and FNZ being an N-terminal part thereof, said at least part of SFS being a C-terminal part of SFS, and said at least part of SEC being a collagen-binding part of SEC~~ which (iv) comprises at least one further antigen that comprises an isolated protein *Streptococcus equi* or a part of said protein, which part comprises at least one antigenic epitope or antigenic determinant of *Streptococcus equi*, and which protein is selected from the group consisting of (a) an isolated protein designated FNZ which comprises the amino acid sequence of SEQ ID NO:2 or an N-terminal fibronectin-binding part of FNZ comprising the amino acid sequence of SEQ ID NO:13, and (b) an isolated protein designated SFS which comprises the amino acid sequence of SEQ ID NO: 3 or a part of SFS comprising the amino acid sequence of SEQ ID NO:10 .

6. (Cancelled)

7. (Currently Amended) A vaccine composition, which comprises the antigenic

composition of ~~any one of claims 1-5~~ claim 1 as an immunizing component, and a pharmaceutically acceptable carrier.

8. (Previously Presented) The vaccine composition of claim 7, which further comprises an adjuvant.

9. (Cancelled)

10. (Original) The vaccine composition of claim 7, which is provided in a physiologically administrable form and suitably is administrable by subcutaneous or intranasal inoculation.

11. (Cancelled)

12. (Withdrawn, Currently Amended) A method for ~~producing~~ preparation of a vaccine ~~an antigen of an antigenic~~ composition ~~of any one of claims 1-5~~ for protecting non-human mammals against infection of *Streptococcus equi*, which vaccine composition contains the antigenic composition of claim 1, which antigenic composition comprises antigens, which antigens are prepared in accordance with a method comprising the following steps: ~~which method comprises~~ (a) providing a DNA fragment encoding said antigen and introducing said fragment into an expression vector; (b) introducing said vector, which contains said DNA fragment, into a compatible host cell; (c) culturing said host cell provided in step (b) under conditions required for expression of the ~~product~~ antigen encoded by said DNA fragment; and

(d) isolating the expressed ~~product~~ antigen from the cultured host cell, and, optionally, (e) purifying the isolated product from step (d) by affinity chromatography or other chromatographic methods known in the art and which method comprises mixing said antigenic composition with a pharmaceutically acceptable carrier.

13. (Withdrawn - Currently Amended) A method for preparation of a vaccine, which vaccine contains as immunizing component, an antigenic composition of ~~any one of claims 1-5~~ claim 1, said method comprising mixing said antigenic composition and a pharmaceutically acceptable carrier.

14. (Cancelled)

15. (Withdrawn, Currently Amended) A method for the production of an antiserum, said method comprising administering an antigenic preparation of ~~any one of claims 1-5~~ claim 1 to an animal host to produce antibodies in said animal host and recovering antiserum containing said antibodies produced in said animal host.

16. (Withdrawn) A method of prophylactic or therapeutic treatment of *S. equi* infection in non-human mammals, suitably horses, comprising administering to said mammal an immunologically effective amount of a vaccine of claim 7.

17. (Withdrawn) A method for protecting horses against *Streptococcus equi* infection,

which comprises inoculating a horse subcutaneously or intranasally with a vaccine of claim 7 to induce an immune response against *Streptococcus equi* in said horse.

18. (Withdrawn) The method of claim 17, wherein an immune response in the form of IgG and/or IgA and/or IgM antibodies in the nasopharyngeal mucus is induced in said horse.

19. (Withdrawn - Currently Amended) Monoclonal antibodies against antigen(s) of the composition of ~~any of claims 1-4~~ claim 1.

20. (Cancelled)

21. (Previously Presented) The vaccine composition of claim 7, which further comprises an adjuvant.

22. (Previously Presented) A method of prophylactic or therapeutic treatment of *S. equi* infection in non-human mammals, comprising administering to said mammal an immunologically effective amount of an antiserum produced according to claim 15.